Persistent Pulmonary Hypertension of the Newborn (PPHN)

Disclaimer: > [!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols.

1. Overview

Persistent Pulmonary Hypertension of the Newborn (PPHN) represents a critical failure of the normal cardiopulmonary transition that occurs at birth. This syndrome is characterized by sustained elevation of pulmonary vascular resistance (PVR) after delivery, leading to right-to-left extrapulmonary shunting of deoxygenated blood through fetal circulatory pathways—primarily the foramen ovale and ductus arteriosus—resulting in severe hypoxemia disproportionate to the degree of parenchymal lung disease. [1,2]

In utero, the pulmonary vasculature maintains high resistance due to low oxygen tension, active vasoconstriction, and mechanical compression by fluid-filled alveoli. The first breath and umbilical cord clamping trigger a dramatic 8-to-10-fold decrease in PVR through multiple mechanisms including increased oxygen tension, physical expansion of the lungs, and release of vasodilatory mediators. When this transition fails, pulmonary arterial pressure remains at or above systemic levels, perpetuating fetal circulation patterns in the extrauterine environment. [3]

PPHN is not a single disease entity but rather a clinical syndrome arising from diverse etiologies including pulmonary parenchymal disease (maladaptation), pulmonary hypoplasia (maldevelopment), and idiopathic pulmonary vascular disease. Understanding these mechanistic subtypes is essential for targeted therapeutic intervention. [1,4]

Image: Fetal Circulation

Image

---

2. Visual Summary Panel

Image Integration Plan

[!NOTE] Image Generation Status: Diagrams illustrating shunting mechanisms, echocardiographic findings, and therapeutic pathways are queued for generation.

Key Diagnostic Triad

1. Severe Hypoxemia: Profound cyanosis and hypoxemia disproportionate to chest radiograph findings, often refractory to supplemental oxygen.
2. Labile Saturations: "Flip-flop" circulation characterized by precipitous desaturation episodes triggered by minimal stimulation, handling, or suctioning due to acute pulmonary vasoconstrictor responses.
3. Differential Cyanosis: Pre-ductal saturations (right hand) exceeding post-ductal saturations (lower extremities) by > 10%, indicative of right-to-left ductal shunting when pulmonary arterial pressure exceeds systemic pressure.

---

3. Epidemiology

Incidence and Demographics

PPHN occurs in approximately 1.9 to 2.0 per 1,000 live births, representing a significant cause of neonatal morbidity and mortality in term and near-term infants. [5] The condition demonstrates several demographic patterns:

• Gestational Age: Predominantly affects term and late preterm infants (≥34 weeks). PPHN is rare in extremely premature infants due to incomplete muscularization of pulmonary arterioles. [1]
• Birth Weight: Most cases occur in infants with birth weight > 2500g, though severe pulmonary hypoplasia (e.g., congenital diaphragmatic hernia) can affect infants across weight categories.
• Sex Distribution: Slight male predominance has been reported in some cohorts.
• Geographic Variation: Higher incidence reported at altitude, potentially related to chronic hypoxia effects on pulmonary vascular development.

Mortality and Morbidity

Despite therapeutic advances including inhaled nitric oxide and extracorporeal membrane oxygenation (ECMO), PPHN continues to carry significant mortality:

• Overall Mortality: 4-33% depending on etiology and severity, with contemporary series reporting 7-10% mortality in centers with ECMO capability. [6]
• Etiology-Specific Mortality: Highest in congenital diaphragmatic hernia (30-50%), intermediate in idiopathic PPHN (10-15%), lowest in meconium aspiration syndrome (5-10%).
• Long-Term Neurodevelopmental Impairment: 7-25% of survivors demonstrate significant neurodevelopmental sequelae at 18-24 months, predominantly related to hypoxic-ischemic brain injury and prolonged critical illness. [7]
• Chronic Pulmonary Disease: 10-25% develop bronchopulmonary dysplasia or chronic lung disease requiring prolonged oxygen therapy.

Risk Factors

Several maternal and neonatal factors increase PPHN risk:

Maternal Factors:

• Late pregnancy SSRI exposure (3-6 fold increased risk)
• NSAID use after 32 weeks gestation (prostaglandin inhibition causing in utero ductal constriction)
• Maternal diabetes (polycythemia, metabolic derangements)
• Maternal obesity and smoking
• Cesarean section without labor (delayed fetal lung fluid clearance)

Neonatal Factors:

• Perinatal asphyxia and acidosis
• Meconium aspiration syndrome
• Early-onset sepsis (Group B Streptococcus, E. coli)
• Pulmonary hypoplasia (congenital diaphragmatic hernia, oligohydramnios sequence)
• Respiratory distress syndrome
• Congenital pneumonia

---

4. Pathophysiology

PPHN pathophysiology is classically organized into three mechanistic categories, though significant overlap exists in clinical practice. [1,8]

A. Maladaptation (Acute Pulmonary Vasoconstriction)

This represents abnormal pulmonary vascular reactivity in structurally normal lungs with normal vascular development. The pulmonary vasculature constricts in response to perinatal stressors, failing to undergo the normal postnatal decrease in PVR.

Mechanisms:

1. Hypoxia-Induced Vasoconstriction: Hypoxia triggers pulmonary arterial smooth muscle contraction via hypoxia-inducible factor (HIF) pathways, inhibition of voltage-gated potassium channels, and calcium influx. This physiologic protective mechanism in utero becomes pathologic postnatally.

2. Acidosis: Both respiratory and metabolic acidosis are potent pulmonary vasoconstrictors. Acidosis inhibits endothelial nitric oxide synthase (eNOS), reduces cyclic GMP production, and directly affects smooth muscle contractility.

3. Endothelial Dysfunction: Impaired production or activity of vasodilatory mediators including nitric oxide (NO), prostacyclin (PGI2), and endothelium-derived hyperpolarizing factor (EDHF), coupled with increased production of vasoconstrictors such as endothelin-1 and thromboxane A2.

4. Parenchymal Lung Disease: Conditions causing alveolar hypoxia and mechanical lung dysfunction perpetuate vasoconstriction:

   • Meconium Aspiration Syndrome (MAS): Airway obstruction, chemical pneumonitis, surfactant inactivation, and inflammatory mediator release
   • Respiratory Distress Syndrome (RDS): Surfactant deficiency in late preterm infants
   • Pneumonia/Sepsis: Bacterial endotoxins directly induce pulmonary vasoconstriction and inflammatory cascades
   • Transient Tachypnea of the Newborn (TTN): Delayed fetal lung fluid clearance

Clinical Conditions:

• Perinatal asphyxia
• Meconium aspiration syndrome (most common, 30-40% of PPHN cases)
• Sepsis and pneumonia (Group B Streptococcus, E. coli)
• Respiratory distress syndrome

B. Maldevelopment (Pulmonary Hypoplasia)

Structural reduction in pulmonary vascular cross-sectional area due to decreased lung growth and vascular development. The diminished vascular bed has intrinsically elevated resistance even without active vasoconstriction.

Mechanisms:

1. Decreased Vessel Number: Reduced branching and arborization of pulmonary arteries during critical developmental windows (16-24 weeks gestation for conducting vessels, 24-40 weeks for intra-acinar vessels).

2. Decreased Alveolar Surface Area: Fewer alveoli reduce the capillary bed available for gas exchange.

3. Impaired Angiogenesis: Disruption of vascular endothelial growth factor (VEGF) signaling and other pro-angiogenic pathways.

Clinical Conditions:

• Congenital Diaphragmatic Hernia (CDH): Compression of developing lung by herniated abdominal viscera causes bilateral pulmonary hypoplasia (ipsilateral > contralateral). CDH-associated PPHN is often severe and persistent. [9]
• Oligohydramnios Sequence: Prolonged oligohydramnios from any cause (renal agenesis/dysplasia, chronic amniotic fluid leak) results in thoracic compression and pulmonary hypoplasia
• Space-Occupying Lesions: Large congenital pulmonary airway malformations (CPAM), pleural effusions, or masses

C. Idiopathic PPHN (Abnormal Pulmonary Vascular Remodeling)

Also termed "black lung PPHN" due to the characteristic appearance of normal-appearing lungs on chest radiograph despite severe hypoxemia. This represents intrinsic abnormality of pulmonary vascular structure and function in the absence of identifiable parenchymal disease or pulmonary hypoplasia.

Mechanisms:

1. Abnormal Vascular Remodeling: Increased pulmonary arterial smooth muscle mass extending distally into normally non-muscularized intra-acinar arterioles. Medial hypertrophy of small muscular arteries increases vascular resistance and reactivity.

2. Adventitial Thickening: Excessive deposition of extracellular matrix proteins (collagen, elastin, fibronectin) in the adventitia of pulmonary arteries.

3. Endothelial Dysfunction: Primary abnormalities in endothelial NO production, prostacyclin synthesis, or cyclic nucleotide signaling independent of acute stressors.

4. In Utero Vascular Programming: Prenatal exposures that induce pathologic vascular remodeling:

   • Maternal SSRI Use: Selective serotonin reuptake inhibitors in late pregnancy are associated with 3-6 fold increased PPHN risk. Serotonin is a pulmonary vasoconstrictor and mitogen for smooth muscle cells.
   • NSAID Exposure: Indomethacin and other NSAIDs used for tocolysis can cause in utero ductal constriction and pulmonary vascular remodeling.
   • Chronic Hypoxia: Maternal smoking, high altitude, placental insufficiency

Genetic Factors: Emerging evidence suggests polymorphisms in genes regulating vascular tone (eNOS, endothelin receptor, serotonin transporter) may confer susceptibility.

Molecular Mechanisms: The Nitric Oxide-cGMP Pathway

Understanding the molecular basis of pulmonary vascular tone is fundamental to PPHN management, particularly the therapeutic rationale for inhaled nitric oxide. [10]

Normal Pulmonary Vasodilation:

1. NO Production: Endothelial nitric oxide synthase (eNOS) catalyzes conversion of L-arginine to L-citrulline and nitric oxide in pulmonary vascular endothelial cells. Multiple stimuli activate eNOS including shear stress, oxygen, and receptor-mediated signals (acetylcholine, bradykinin).

2. NO Diffusion: Lipophilic NO freely diffuses from endothelial cells into adjacent smooth muscle cells.

3. Cyclic GMP Production: NO activates soluble guanylate cyclase (sGC) in smooth muscle, catalyzing conversion of GTP to cyclic GMP (cGMP).

4. Smooth Muscle Relaxation: Elevated cGMP activates protein kinase G (PKG), which phosphorylates multiple targets leading to reduced intracellular calcium and smooth muscle relaxation.

5. Phosphodiesterase Degradation: Cyclic GMP is metabolized by phosphodiesterase type 5 (PDE5), terminating the vasodilatory signal.

PPHN Defects:

• Reduced eNOS expression and activity
• Decreased NO bioavailability (enhanced scavenging by reactive oxygen species)
• Reduced sGC expression or responsiveness
• Increased PDE5 activity (enhanced cGMP degradation)
• Impaired downstream signaling

Therapeutic Implications:

• Inhaled NO: Bypasses defective endogenous NO production, directly activating sGC
• PDE5 Inhibitors (Sildenafil): Prevent cGMP breakdown, prolonging vasodilation
• sGC Stimulators: Emerging therapies to enhance cGMP production

---

5. Clinical Presentation

Timing of Presentation

PPHN typically manifests within the first 24 hours of life, most commonly in the immediate postnatal period (first 12 hours). However, presentation timing varies by etiology:

• Immediate (0-6 hours): Severe perinatal asphyxia, idiopathic PPHN, meconium aspiration
• Early (6-24 hours): Sepsis, pneumonia, TTN with secondary pulmonary hypertension
• Delayed (24-72 hours): Occasionally seen in evolving chronic lung disease or with late deterioration

Cardinal Features

1. Hypoxemia and Cyanosis

• Central cyanosis (lips, tongue, mucous membranes)
• Severe hypoxemia often refractory to oxygen supplementation
• Oxygen saturations typically less than 85-90% in severe cases
• Disproportionate hypoxemia relative to chest radiograph abnormalities (key distinguishing feature)

2. Respiratory Distress

• Tachypnea (respiratory rate > 60/min)
• Grunting (forced expiration against partially closed glottis to maintain functional residual capacity)
• Intercostal, subcostal, and suprasternal retractions
• Nasal flaring
• Severity varies from mild tachypnea to respiratory failure requiring mechanical ventilation

3. Differential Cyanosis

• Pre-ductal saturation (right hand) > post-ductal saturation (lower extremities or left hand) by > 10%
• Indicates right-to-left shunting through patent ductus arteriosus when pulmonary artery pressure exceeds aortic pressure
• May be absent if significant atrial level shunting occurs or if ductus arteriosus closes
• Reverse Differential Cyanosis (rare): Post-ductal saturation > pre-ductal saturation suggests transposition of great arteries with coarctation or interrupted aortic arch—requires immediate cardiology consultation

4. Hemodynamic Instability

• Systemic hypotension from reduced left ventricular output (LV preload reduced by right-to-left atrial shunting)
• Poor perfusion with prolonged capillary refill time (> 3 seconds)
• Weak peripheral pulses
• Metabolic acidosis reflecting tissue hypoperfusion
• Frank shock in severe cases

5. Lability

• Profound desaturation episodes with minimal stimulation ("flip-flop" physiology)
• Handling, suctioning, painful procedures, or noise can trigger acute pulmonary vasoconstrictor crises
• Rapid, unpredictable fluctuations in oxygenation
• Highlights the need for minimal stimulation protocols

Associated Clinical Features

Cardiac Examination:

• Prominent right ventricular impulse (parasternal heave)
• Loud second heart sound (P2 component accentuated due to elevated pulmonary artery pressure)
• Systolic murmur of tricuspid regurgitation (best heard at left lower sternal border, increases with inspiration)
• Gallop rhythm in severe ventricular dysfunction
• Hepatomegaly from venous congestion if significant tricuspid regurgitation present

Underlying Disease Manifestations:

• Meconium staining of skin, nails, umbilical cord
• Signs of asphyxia (encephalopathy, multiorgan dysfunction)
• Sepsis features (temperature instability, lethargy, poor feeding)
• Dysmorphic features suggesting genetic syndrome
• Asymmetric chest wall movement or scaphoid abdomen (congenital diaphragmatic hernia)

---

6. Clinical Examination

Systematic Examination Approach

Inspection:

1. Color Assessment: Central vs peripheral cyanosis, mottling, pallor
2. Respiratory Pattern: Rate, depth, work of breathing, symmetry of chest wall movement
3. Perfusion: Capillary refill time (normal less than 3 seconds), peripheral temperature, color
4. Dysmorphic Features: Evaluate for syndromic diagnoses

Pulse Oximetry Protocol:

Critical diagnostic maneuver requiring simultaneous pre- and post-ductal measurements:

1. Pre-Ductal: Right hand (receives blood from ascending aorta proximal to ductus arteriosus insertion)
2. Post-Ductal: Either foot or left hand (receives blood distal to ductus insertion, potentially mixed with right-to-left shunt)

Interpretation:

• Difference > 10%: Strongly suggests PPHN with ductal-level right-to-left shunting
• Difference 5-10%: Possible PPHN, correlate with echocardiography
• No Difference: Does not exclude PPHN (may have predominant atrial-level shunting or closed ductus)

Cardiovascular Examination:

1. Precordial Palpation:

   • Right ventricular heave (parasternal lift)
   • Displaced or diffuse apical impulse suggests cardiomegaly
   • Thrill suggests structural heart disease

2. Auscultation:

   • S1: Usually normal
   • S2: Loud, single (inaudible A2-P2 split due to elevated pulmonary pressure), or widely split (right bundle branch block, severe RV dysfunction)
   • Murmurs: Tricuspid regurgitation (holosystolic, left lower sternal border), pulmonary regurgitation (early diastolic, left upper sternal border), patent ductus arteriosus (continuous machinery murmur, left infraclavicular)
   • S3/S4 Gallop: Ventricular dysfunction

3. Peripheral Pulses: Volume, symmetry (coarctation or interrupted arch), brachial-femoral delay

4. Blood Pressure: Four-limb blood pressures to exclude coarctation (> 10 mmHg gradient upper-to-lower extremity)

5. Hepatomegaly: Liver edge > 2 cm below costal margin suggests systemic venous congestion

Respiratory Examination:

1. Inspection: Symmetry, scaphoid abdomen (CDH), pectus deformity
2. Palpation: Tracheal position, chest expansion symmetry
3. Percussion: Dullness (effusion, consolidation) vs hyperresonance (pneumothorax, CDH)
4. Auscultation: Air entry symmetry, crackles (pulmonary edema, pneumonia), decreased sounds (effusion, pneumothorax, lung hypoplasia)

Neurological Examination:

• Level of consciousness and responsiveness
• Tone, posture, primitive reflexes
• Signs of hypoxic-ischemic encephalopathy (seizures, abnormal movements)
• Anterior fontanelle (sunken in dehydration, full/tense in cerebral edema or intracranial hemorrhage)

---

7. Investigations

PPHN diagnosis requires integration of clinical features, laboratory data, imaging, and most critically, echocardiography. The primary investigative goals are: (1) confirm PPHN, (2) exclude structural heart disease, (3) identify underlying etiology, (4) assess severity, and (5) monitor response to therapy. [11]

A. Echocardiography

Gold standard investigation for PPHN diagnosis and essential to exclude structural congenital heart disease. Should be performed urgently in any neonate with suspected PPHN.

Key Echocardiographic Findings:

1. Structural Assessment (Exclude Congenital Heart Disease):

• Atrial and ventricular situs, size, and function
• Atrioventricular and ventriculoarterial connections
• Pulmonary venous return (exclude total anomalous pulmonary venous return)
• Great artery relationships (exclude transposition)
• Ductal and atrial septal anatomy

Critical: Many cyanotic congenital heart lesions can mimic PPHN clinically. Echocardiography differentiates structural disease requiring cardiac surgery from PPHN requiring medical management.

2. Evidence of Elevated Pulmonary Pressure:

Septal Configuration:

• Normal: Interventricular septum is convex toward RV (LV pressure > RV pressure)
• Flattened Septum: RV pressure approaching LV pressure (systolic PAP 50-75% systemic)
• Leftward Septal Bowing: RV pressure exceeds LV pressure (systolic PAP > systemic)
• Assess in multiple views (parasternal short axis most sensitive)

Tricuspid Regurgitation Jet Velocity:

• Doppler interrogation of TR jet allows estimation of RV systolic pressure
• Modified Bernoulli Equation: RV systolic pressure = 4(V)² + estimated RA pressure
• TR velocity > 3 m/s suggests systolic PAP > 40 mmHg
• TR velocity > 3.5 m/s suggests severe pulmonary hypertension

Pulmonary Regurgitation:

• End-diastolic PR velocity allows estimation of diastolic PAP and mean PAP
• Useful for assessing pulmonary pressure when TR jet not well seen

3. Shunting Patterns:

Patent Ductus Arteriosus:

• Bidirectional or Pure Right-to-Left Flow: Diagnostic of suprasystemic pulmonary pressure
• Size and Duration of Shunting: Guide therapeutic decisions
• Color Doppler interrogation from ductal and suprasternal views

Patent Foramen Ovale:

• Right-to-left atrial shunting (agitated saline contrast study shows right-to-left passage)
• May be predominant shunt if ductus closes

4. Ventricular Function Assessment:

• RV systolic function (TAPSE, RV fractional area change, S' velocity)
• LV systolic function (shortening fraction, ejection fraction)
• Diastolic function (mitral inflow patterns, tissue Doppler)
• Identifies myocardial dysfunction requiring inotropic support

5. Serial Echocardiography:

• Repeat studies to assess response to therapy
• Guide weaning of pulmonary vasodilators
• Detect complications (e.g., LV dysfunction with aggressive pulmonary vasodilation)

B. Arterial Blood Gas Analysis

Critical for:

• Confirming hypoxemia
• Assessing ventilation (PaCO2)
• Evaluating acid-base status (pH, base deficit)
• Calculating oxygenation indices
• Monitoring response to therapy

Sampling Sites:

• Pre-ductal (Right radial artery): Reflects cerebral and upper body oxygenation
• Post-ductal (Umbilical or posterior tibial artery): Reflects lower body oxygenation
• Dual sampling demonstrates differential oxygenation in ductal-level shunting

Typical Blood Gas Findings in PPHN:

• Hypoxemia: PaO2 less than 50-60 mmHg despite FiO2 1.0
• Pre-Post Ductal PaO2 Gradient: Pre-ductal PaO2 exceeds post-ductal by > 15-20 mmHg
• Variable PaCO2: May be low (hyperventilation), normal, or elevated depending on lung disease severity and ventilation strategy
• Metabolic Acidosis: Base deficit > 5-10 mmol/L reflects tissue hypoperfusion
• Respiratory Acidosis: pH less than 7.30 if significant lung disease or hypoventilation

C. Oxygenation Assessment Indices

1. Oxygenation Index (OI)

The most widely used severity metric, incorporating oxygenation and ventilatory support intensity:

Formula: OI = (Mean Airway Pressure × FiO2 × 100) / PaO2

Where:

• Mean Airway Pressure (MAP) in cmH2O
• FiO2 as fraction (0.21-1.0), often multiplied by 100
• PaO2 in mmHg

Interpretation:

• OI less than 10: Mild respiratory failure
• OI 10-15: Moderate respiratory failure
• OI 15-25: Severe respiratory failure, consider inhaled nitric oxide
• OI 25-40: Very severe, likely iNO candidate, prepare for escalation
• OI > 40: ECMO threshold criteria in many centers

Serial OI measurements track disease progression and therapeutic response. Increasing OI despite therapy indicates treatment failure.

2. A-a Gradient (Alveolar-arterial Oxygen Gradient)

Assesses efficiency of gas exchange:

Formula: A-a gradient = PAO2 - PaO2

Where PAO2 = (FiO2 × [Patm - PH2O]) - (PaCO2/RQ)

Normal A-a gradient in neonates: less than 20-30 mmHg on room air

Elevated A-a gradient (> 400-500 mmHg on FiO2 1.0) indicates severe gas exchange impairment from shunting or V/Q mismatch.

3. Hyperoxygenation (Hyperoxia) Test

Differentiates cyanotic congenital heart disease from pulmonary causes of hypoxemia (including PPHN).

Protocol:

1. Measure baseline PaO2 on room air (FiO2 0.21)
2. Administer 100% oxygen (FiO2 1.0) for 10 minutes via headbox or brief intubation
3. Repeat arterial blood gas

Interpretation:

• PaO2 > 150-200 mmHg: Pulmonary disease (oxygen overcomes V/Q mismatch)
• PaO2 100-150 mmHg: Intermediate, likely partial shunt
• PaO2 less than 100 mmHg: Fixed right-to-left shunt (cyanotic CHD or severe PPHN)

Limitations:

• High oxygen exposure may be harmful
• Test is unsafe in unstable infants
• Echocardiography provides more definitive diagnosis
• Rarely performed in modern practice, largely supplanted by echocardiography

D. Chest Radiography

Chest X-ray appearance varies with underlying etiology but is essential for differential diagnosis.

Radiographic Patterns:

1. Clear or Oligemic Lung Fields:

• Idiopathic PPHN: Often normal or near-normal parenchyma with decreased pulmonary vascular markings
• Cardiac silhouette may be normal or mildly enlarged
• "Black lung" or "dark lung" PPHN

2. Parenchymal Opacification:

• Meconium Aspiration Syndrome: Patchy, asymmetric opacities; hyperinflation; possible pneumothorax
• Respiratory Distress Syndrome: Diffuse granular opacification, air bronchograms (late preterm infants)
• Pneumonia/Sepsis: Variable infiltrates, often bilateral

3. Structural Abnormalities:

• Congenital Diaphragmatic Hernia: Bowel gas pattern in hemithorax, mediastinal shift, absence of normal abdominal gas pattern
• Pulmonary Hypoplasia: Small volume lung fields
• Pleural Effusions: Blunted costophrenic angles, density along lateral chest wall

4. Air Leak Syndromes:

• Pneumothorax, pneumomediastinum, pneumopericardium (complications of mechanical ventilation)

Image: PPHN CXR

Image

Serial Chest Radiographs monitor evolution of parenchymal disease, detect complications (air leak), and assess endotracheal tube position.

E. Laboratory Investigations

Complete Blood Count:

• White blood cell count and differential (sepsis evaluation)
• Hemoglobin and hematocrit (polycythemia increases blood viscosity and pulmonary resistance; anemia reduces oxygen-carrying capacity)
• Platelet count (thrombocytopenia in sepsis or DIC)

Infection Screen:

• Blood culture (bacterial sepsis)
• C-reactive protein, procalcitonin (inflammatory markers)
• Lumbar puncture if meningitis suspected (after stabilization)

Metabolic Panel:

• Glucose (hypoglycemia common in stressed neonates)
• Electrolytes (sodium, potassium, calcium, magnesium)
• Renal function (creatinine, BUN)
• Liver function (hypoxic hepatitis in severe cases)

Coagulation Studies:

• PT, PTT, fibrinogen (disseminated intravascular coagulation in severe sepsis/asphyxia)

Lactate:

• Elevated lactate (> 4 mmol/L) indicates tissue hypoperfusion and anaerobic metabolism
• Serial lactate measurements guide resuscitation adequacy

F. Cranial Ultrasound

• Screen for intracranial hemorrhage, periventricular leukomalacia
• Assess for hypoxic-ischemic injury
• Particularly important in asphyxiated infants or those with hemodynamic instability

G. Genetic and Metabolic Testing

Consider in atypical presentations or when syndromic diagnosis suspected:

• Chromosomal microarray
• Targeted gene panels (CDH-associated genes, pulmonary hypertension genes)
• Metabolic screening if inborn error of metabolism suspected

---

8. Management

PPHN management requires a multifaceted approach targeting the underlying cause, optimizing pulmonary vasodilation, supporting systemic hemodynamics, and minimizing iatrogenic injury. The overarching goal is to reduce pulmonary vascular resistance (PVR) relative to systemic vascular resistance (SVR), thereby reversing pathologic right-to-left shunting and improving systemic oxygenation. [12,13]

A. General Supportive Measures: "Pink, Warm, Sweet, Still"

1. Minimal Handling ("Still")

The single most important non-pharmacologic intervention. Infants with PPHN exhibit profound lability, with minor stimulation triggering pulmonary vasoconstrictor crises and life-threatening desaturation.

Principles:

• Cluster necessary care activities
• Sedation and analgesia (see below)
• Minimize noise, light, and environmental stimulation
• Limit suctioning to essential indications only
• Use "hands-off" monitoring where possible
• Avoid unnecessary examinations

Clinical Adage: "Thumping the incubator kills the baby" underscores the extreme sensitivity to stimulation.

2. Sedation and Analgesia

Indications: All mechanically ventilated infants with PPHN

Agents:

• Morphine: 50-100 mcg/kg loading dose, then 10-20 mcg/kg/hr continuous infusion

  • Provides analgesia and sedation
  • Reduces endogenous catecholamine surges
  • "Caution: May cause hypotension (histamine release, reduced sympathetic tone)"

• Fentanyl: 1-2 mcg/kg bolus, then 1-5 mcg/kg/hr infusion

  • More potent analgesia with less hemodynamic effect than morphine
  • Preferred in hemodynamically unstable infants

• Midazolam: 100-200 mcg/kg loading dose, then 50-200 mcg/kg/hr infusion

  • Anxiolysis and amnesia
  • Reduces agitation-induced vasoconstriction
  • Monitor for hypotension

3. Neuromuscular Blockade (Paralysis)

Indications:

• Severe PPHN with profound lability despite sedation
• Patient-ventilator dyssynchrony
• High-frequency oscillatory ventilation
• Immediately pre-ECMO

Agent:

• Vecuronium: 0.1 mg/kg IV bolus, then 0.05-0.1 mg/kg/hr infusion
• Rocuronium: 0.6-1.0 mg/kg IV bolus, then 0.3-0.6 mg/kg/hr infusion

Caution:

• Use only when sedation/analgesia alone insufficient
• Requires adequate sedation (prevent awareness during paralysis)
• Associated with prolonged muscle weakness, particularly with concurrent corticosteroid use

4. Correction of Acidosis ("Pink")

Both respiratory and metabolic acidosis are potent pulmonary vasoconstrictors. Optimizing pH is critical.

Target pH: 7.30-7.45 (some advocate gentle alkalosis to pH 7.45-7.50)

Respiratory Acidosis Management:

• Optimize ventilation (increase rate or tidal volume)
• Caution: Avoid excessive ventilation causing barotrauma or hypocapnia (cerebral vasoconstriction)

Metabolic Acidosis Management:

• Volume Resuscitation: Restore perfusion if hypovolemic
• Inotropic Support: Improve cardiac output and tissue perfusion
• Sodium Bicarbonate: 1-2 mEq/kg slow IV push if pH less than 7.20-7.25 and adequate ventilation
  • Corrects acidosis but generates CO2 (ensure adequate ventilation)
  • Hyperosmolar; risk of intraventricular hemorrhage in preterm infants
  • Use judiciously

5. Temperature Regulation ("Warm")

Target: Normothermia (36.5-37.5°C)

• Hypothermia increases metabolic oxygen demand and pulmonary vasoconstriction
• Use radiant warmer or incubator with servo-control
• Exception: Therapeutic hypothermia (33.5-34.5°C) for moderate-severe hypoxic-ischemic encephalopathy
  • Cooling for HIE may worsen PPHN; requires careful monitoring and often more aggressive pulmonary vasodilator therapy

6. Glucose Homeostasis ("Sweet")

Target: Euglycemia (70-150 mg/dL or 4-8 mmol/L)

• Hypoglycemia increases catecholamine release and worsens pulmonary vasoconstriction
• Provide adequate glucose delivery (typically 6-8 mg/kg/min)
• Monitor blood glucose every 2-4 hours initially

7. Fluid and Electrolyte Management

• Maintain adequate intravascular volume (CVP 5-8 mmHg if central line present)
• Avoid excessive fluid administration (pulmonary edema, worsening oxygenation)
• Typical initial fluid rate: 60-80 mL/kg/day, adjust based on urine output and electrolytes
• Correct electrolyte abnormalities (hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia)

8. Anemia and Polycythemia Management

• Anemia: Transfuse if Hb less than 12-13 g/dL in critically ill infants (optimize oxygen-carrying capacity)
• Polycythemia: Hematocrit > 65-70% increases blood viscosity and PVR; consider partial exchange transfusion

B. Oxygen Therapy and Ventilation Strategy

Oxygen as a Pulmonary Vasodilator:

Oxygen is one of the most potent pulmonary vasodilators. However, excessive oxygen causes systemic vasodilation and oxygen toxicity.

Target Saturations:

• Pre-ductal (Right Hand): 92-97%
• Avoid excessive hyperoxia (> 97-98%) to prevent ROP and oxygen toxicity
• Avoid hypoxia (less than 90%) to prevent pulmonary vasoconstriction

1. Conventional Mechanical Ventilation (CMV)

Indications: Respiratory failure requiring invasive support

Strategy:

• Gentle Ventilation: Avoid volutrauma and barotrauma
• Peak Inspiratory Pressure (PIP): Minimize (typically 20-28 cmH2O)
• Positive End-Expiratory Pressure (PEEP): 4-6 cmH2O to maintain functional residual capacity
• Inspiratory Time (Ti): 0.35-0.45 seconds
• Rate: 40-60 breaths/min
• FiO2: Titrate to target saturations

"Permissive Hypercapnia":

• Accept PaCO2 45-55 mmHg (or even 55-65 mmHg) if pH > 7.25-7.30
• Reduces ventilator-induced lung injury
• Avoid excessive hyperventilation (historical practice aiming for PaCO2 less than 30 mmHg is harmful)

2. High-Frequency Oscillatory Ventilation (HFOV)

Indications:

• Failure of conventional ventilation (OI > 15-20 despite optimization)
• Severe air leak syndrome or high risk thereof
• Meconium aspiration syndrome with heterogeneous lung disease

Mechanism:

• Delivers very small tidal volumes (1-3 mL/kg) at high frequency (8-15 Hz)
• Maintains optimal lung volume (continuous distending pressure) without high peak pressures
• Reduces volutrauma and barotrauma

Initial Settings:

• Frequency: 10-15 Hz (lower frequency allows greater CO2 elimination)
• Mean Airway Pressure: Start 2-3 cmH2O above CMV MAP, titrate to "optimal lung inflation" on CXR (8-9 posterior ribs visible)
• Amplitude (ΔP): Titrate to visible chest wall vibration and adequate CO2 elimination
• FiO2: Titrate to target saturations

Outcomes:

• May improve oxygenation in selected patients
• No clear mortality benefit over gentle conventional ventilation in RCTs
• Useful adjunct in specific clinical scenarios (MAS, air leak)

3. Surfactant Therapy

Indications:

• PPHN secondary to surfactant deficiency (RDS, MAS with surfactant inactivation)
• Consider in MAS with severe parenchymal disease

Agent and Dose:

• Beractant (Survanta), poractant alfa (Curosurf), or calfactant (Infasurf)
• Follow manufacturer dosing guidelines
• May repeat dose if inadequate response

Mechanism:

• Reduces surface tension, improves lung compliance
• Recruits alveoli, improves V/Q matching
• Reduces PVR by improving lung inflation and oxygenation

C. Pulmonary Vasodilator Therapy

1. Inhaled Nitric Oxide (iNO)

Inhaled nitric oxide is the first-line specific therapy for PPHN, supported by multiple randomized controlled trials demonstrating reduced need for ECMO. [14,15]

Mechanism:

• Selective pulmonary vasodilation without systemic hypotension
• Delivered gas diffuses across alveolar-capillary membrane
• Activates soluble guanylate cyclase in pulmonary vascular smooth muscle
• Increases cyclic GMP, causing smooth muscle relaxation
• Rapidly inactivated by binding to hemoglobin (forms methemoglobin), preventing systemic effects

Indications:

• Hypoxemic respiratory failure with OI ≥15-20
• Echocardiographic confirmation of PPHN
• Exclude or stabilize congenital heart disease

Contraindications:

• Structural heart disease dependent on right-to-left shunt (e.g., critical pulmonary stenosis, hypoplastic left heart)
• Methemoglobinemia (relative contraindication)

Dosing:

• Initial Dose: 20 ppm (parts per million)
• Assess response in 30-60 minutes (improved oxygenation, reduced FiO2 or ventilator support)
• If no response, can trial 40 ppm briefly, but doses > 20 ppm rarely provide additional benefit
• Responders: Sustained improvement in oxygenation (increased PaO2, decreased OI)

Response Rates:

• 50-60% demonstrate significant improvement
• 30-40% show partial response
• 10-20% non-responders

Non-Response Considerations:

• Confirm adequate lung recruitment (optimize ventilation, consider HFOV)
• Exclude structural heart disease
• Evaluate for left ventricular dysfunction
• Consider alternative/adjunctive therapies (sildenafil, milrinone)

Weaning:

• Begin weaning once stable oxygenation and OI less than 10-15
• Gradual reduction: Decrease by 1-5 ppm every 4-6 hours while monitoring oxygenation
• Slow wean is critical: Abrupt discontinuation causes "rebound pulmonary hypertension" with potentially catastrophic desaturation
• Typical duration: 3-7 days (range 1-14+ days)
• Consider sildenafil overlap before discontinuing iNO to prevent rebound

Monitoring:

• Methemoglobin levels: Check 4-6 hours after initiation, then daily
  • Target less than 2.5-3%
  • Elevated levels (> 5%) require iNO dose reduction or discontinuation
• Nitrogen dioxide (NO2): Toxic byproduct; monitor continuously
  • Target less than 2 ppm
• Oxygenation indices: Serial OI, blood gases

Adverse Effects:

• Methemoglobinemia: Dose-dependent (rare at ≤20 ppm)
• Rebound Pulmonary Hypertension: Risk with abrupt discontinuation
• Platelet Dysfunction: Theoretical risk; rarely clinically significant
• Nitrogen Dioxide Toxicity: Rare with modern delivery systems

Image: Inhaled Nitric Oxide

Image

2. Sildenafil (PDE5 Inhibitor)

Phosphodiesterase type 5 inhibitor that prevents degradation of cyclic GMP, prolonging pulmonary vasodilation.

Indications:

• Adjunct to iNO in partial responders or to facilitate iNO weaning
• Alternative when iNO unavailable or as bridge to availability
• Chronic pulmonary hypertension beyond acute neonatal period

Dosing:

• IV Sildenafil: 0.125-0.5 mg/kg/dose every 6-8 hours (loading dose 0.3-0.4 mg/kg)
• Enteral Sildenafil: 0.5-2 mg/kg/dose every 6-8 hours (once tolerating feeds)

Efficacy:

• Improves oxygenation in 40-60% of patients
• May reduce ECMO need (less robust evidence than iNO)
• Facilitates iNO weaning when started 24 hours before iNO discontinuation

Adverse Effects:

• Systemic Hypotension: More common than with iNO (not selective)
• Monitor blood pressure closely
• May require inotropic support

Evidence:

• Multiple small RCTs and observational studies show benefit
• Not FDA-approved for neonatal use (off-label)
• Some controversy regarding enteral use in preterm infants (association with mortality in BPD trial, though different population)

3. Milrinone (PDE3 Inhibitor)

Phosphodiesterase type 3 inhibitor with both inotropic and vasodilatory properties.

Mechanism:

• Increases cardiac contractility (positive inotropy)
• Pulmonary and systemic vasodilation
• Improves both right and left ventricular function

Indications:

• PPHN with myocardial dysfunction (RV or LV impairment on echocardiography)
• Low cardiac output state
• Adjunct in iNO partial responders

Dosing:

• Loading Dose: 50 mcg/kg IV over 30-60 minutes (optional, often omitted in hypotensive patients)
• Maintenance Infusion: 0.33-0.75 mcg/kg/min

Advantages:

• Improves cardiac output in addition to vasodilation
• Useful when hemodynamic compromise beyond pure pulmonary hypertension

Adverse Effects:

• Hypotension: Monitor BP and reduce dose if necessary
• Thrombocytopenia: Rare
• Arrhythmias: Rare in neonates

4. Prostacyclin Analogues (Epoprostenol, Iloprost)

Prostacyclin (PGI2) is an endogenous pulmonary vasodilator and platelet inhibitor.

Indications:

• Refractory PPHN unresponsive to iNO and sildenafil
• Not routinely used; reserve for severe cases

Agents:

• Inhaled Iloprost: Selective pulmonary vasodilation
• IV Epoprostenol: Systemic hypotension risk

Limitations:

• Limited neonatal safety data
• Systemic hypotension
• Complex administration

D. Cardiovascular Support and Inotropic Therapy

PPHN management requires maintaining systemic vascular resistance (SVR) above pulmonary vascular resistance (PVR) to reverse right-to-left shunting. Systemic hypotension worsens shunt fraction and exacerbates hypoxemia.

Hemodynamic Goals:

• Mean Arterial Pressure: > 40-45 mmHg in term infants
• Maintain SVR > PVR: Judicious use of vasopressors
• Adequate Cardiac Output: Ensure both RV and LV function adequate

1. Volume Resuscitation

First-line for hypotension if inadequate intravascular volume suspected.

• 0.9% Normal Saline: 10 mL/kg IV bolus over 30 minutes
• May repeat if inadequate response (max 20-30 mL/kg in first hours)
• Reassess after each bolus; avoid fluid overload

2. Vasopressor/Inotrope Selection

Dopamine:

• Dose: 5-20 mcg/kg/min IV infusion
• Effects: Dose-dependent (low dose: renal vasodilation; mid dose: inotropy; high dose: vasoconstriction)
• Use: First-line inotrope/vasopressor in neonatal hypotension
• Increases SVR and cardiac contractility

Dobutamine:

• Dose: 5-20 mcg/kg/min IV infusion
• Effects: Positive inotropy, mild vasodilation
• Use: Low cardiac output with adequate blood pressure
• Consider in myocardial dysfunction
• Often combined with dopamine or norepinephrine

Epinephrine (Adrenaline):

• Dose: 0.05-1.0 mcg/kg/min IV infusion
• Effects: Potent inotrope and vasoconstrictor
• Use: Refractory hypotension, cardiogenic shock
• Risk of tachycardia, arrhythmias

Norepinephrine (Noradrenaline):

• Dose: 0.05-1.0 mcg/kg/min IV infusion
• Effects: Potent vasoconstriction (alpha agonist), mild inotropy
• Use: Refractory hypotension with adequate cardiac output
• Preferred for maintaining SVR > PVR in PPHN
• Monitor perfusion (may reduce peripheral blood flow)

Vasopressin:

• Dose: 0.0003-0.002 units/kg/min (0.3-2 milliunits/kg/min) IV infusion
• Effects: Selective systemic vasoconstriction, may spare pulmonary vasculature
• Use: Catecholamine-resistant hypotension
• Emerging evidence in neonatal shock, limited data specific to PPHN

Milrinone:

• As discussed above (PDE3 inhibitor)
• Inotrope and vasodilator
• Particularly useful with LV dysfunction

Strategy:

• Start with dopamine (first-line)
• Add norepinephrine if hypotension persists (maintain SVR)
• Add dobutamine or milrinone if low cardiac output despite adequate BP
• Titrate to effect while monitoring perfusion, BP, and lactate clearance

E. Extracorporeal Membrane Oxygenation (ECMO)

ECMO provides mechanical cardiopulmonary support, allowing the lungs to "rest" and pulmonary vascular remodeling to occur in severe, refractory PPHN. [16]

Indications (ECMO Criteria):

Oxygenation-Based:

• Oxygenation Index > 40 on two arterial blood gases 4-6 hours apart despite maximal medical therapy (including iNO)
• Persistent hypoxemia: PaO2 less than 40-50 mmHg despite FiO2 1.0, iNO, optimal ventilation

Alternative Criteria (varies by center):

• A-a gradient > 610 mmHg for > 8-12 hours
• Acute deterioration (cardiac arrest, unresponsive hypotension)

Contraindications:

Absolute:

• Gestational age less than 34 weeks or birth weight less than 2 kg (relative in modern era; some centers accept ≥32 weeks)
• Severe intracranial hemorrhage (Grade 3-4 IVH)
• Lethal congenital anomalies or chromosomal disorders incompatible with life
• Irreversible severe neurologic injury

Relative:

• Mechanical ventilation > 10-14 days (risk of irreversible lung injury)
• Severe coagulopathy
• Significant intracranial hemorrhage

ECMO Modes:

Venoarterial (VA) ECMO:

• Provides both cardiac and respiratory support
• Cannulation: Right internal jugular vein (drainage) and right common carotid artery (reinfusion)
• Preferred in PPHN (many patients have hemodynamic instability)
• Requires carotid ligation (long-term neurodevelopmental effects controversial)

Venovenous (VV) ECMO:

• Provides respiratory support only (requires adequate cardiac function)
• Cannulation: Right internal jugular vein (double-lumen catheter allows drainage and reinfusion)
• Preserves carotid artery
• Limited use in PPHN due to frequent hemodynamic compromise

ECMO Outcomes in PPHN:

• Survival: 75-85% overall
• PPHN-Specific Survival: 75-90% (highest survival among ECMO indications)
• Survival by Etiology:
  • "Meconium aspiration syndrome: 90-95%"
  • "Idiopathic PPHN: 80-90%"
  • "Sepsis/pneumonia: 70-80%"
  • "Congenital diaphragmatic hernia: 50-60%"

Complications:

• Neurologic: Intracranial hemorrhage (10-15%), stroke (5%), seizures
• Hemorrhagic: Bleeding (systemic anticoagulation required)
• Infectious: Cannula-related infections
• Mechanical: Circuit malfunction, air embolism (rare)

Duration:

• Typically 5-10 days (range 3-21+ days)
• Longer runs associated with increased complication risk
• Wean as pulmonary hypertension resolves (assessed by echocardiography and trial off-support)

F. Adjunctive and Supportive Therapies

1. Corticosteroids

Hydrocortisone:

• Indications: Refractory hypotension unresponsive to fluid and vasopressors (possible relative adrenal insufficiency)
• Dose: Stress-dose hydrocortisone 1-2 mg/kg/dose IV every 8-12 hours
• Evidence: Limited specific data in PPHN; extrapolated from catecholamine-resistant hypotension studies

Dexamethasone:

• Occasionally used for severe, persistent pulmonary hypertension
• Anti-inflammatory effects
• Very limited evidence; not routine

2. Surfactant

As discussed above, for RDS or MAS with surfactant dysfunction.

3. Antibiotics

Broad-spectrum antibiotics for sepsis evaluation (ampicillin + gentamicin, or local protocol) pending cultures. Discontinue if cultures negative and clinical picture not consistent with infection.

4. Nutrition

• Initially: NPO (nil per os) with IV fluids and parenteral nutrition
• Enteral Feeding: Initiate cautiously once stable (reduced risk of necrotizing enterocolitis concerns in stable infants)
• Adequate caloric intake for recovery and growth

G. Novel and Experimental Therapies

1. Bosentan (Endothelin Receptor Antagonist)

• Blocks endothelin-1 (a potent vasoconstrictor) effects
• Oral therapy
• Limited neonatal data; hepatotoxicity concerns
• Investigational for chronic neonatal pulmonary hypertension

2. Riociguat (Soluble Guanylate Cyclase Stimulator)

• Stimulates sGC independent of NO
• Potentially useful in iNO non-responders
• No neonatal safety/efficacy data

3. Stem Cell Therapies

• Mesenchymal stem cells (MSCs) in preclinical studies
• Anti-inflammatory and pro-angiogenic properties
• Very early experimental stage

---

9. Complications

PPHN and its intensive management strategies carry significant risks of both acute and long-term complications. [17]

A. Pulmonary Complications

1. Air Leak Syndromes

Mechanical ventilation, particularly with high peak pressures, causes alveolar rupture and air leak.

Types:

• Pneumothorax: Air in pleural space; may be tension (mediastinal shift, cardiovascular compromise) requiring emergent needle decompression and chest tube placement
• Pneumomediastinum: Air in mediastinum; usually self-limited but can progress to pneumothorax
• Pneumopericardium: Air in pericardial space; may cause tamponade requiring pericardial drainage
• Pulmonary Interstitial Emphysema (PIE): Air dissecting along perivascular sheaths; worsens lung compliance and oxygenation

Management:

• Minimize ventilator pressures ("gentle ventilation")
• Chest tube drainage for pneumothorax
• Reduce ventilator support as tolerated

2. Bronchopulmonary Dysplasia (BPD) / Chronic Lung Disease

Prolonged mechanical ventilation, high oxygen concentrations, and inflammation cause chronic lung injury.

Definition: Oxygen requirement at 36 weeks postmenstrual age (in preterm) or ≥28 days of age (in term infants)

Incidence: 10-25% of survivors, higher in CDH or severe MAS

Risk Factors:

• Prolonged high FiO2 exposure
• Barotrauma/volutrauma from mechanical ventilation
• Underlying lung hypoplasia

Long-Term Sequelae:

• Reactive airway disease
• Exercise intolerance
• Increased respiratory infections
• Persistent or recurrent pulmonary hypertension

3. Chronic Pulmonary Hypertension

Subset of infants develop persistent pulmonary hypertension beyond neonatal period.

Management:

• Chronic sildenafil therapy
• Bosentan (endothelin antagonist)
• Pulmonary hypertension clinic follow-up
• Serial echocardiography

B. Neurologic Complications

Neurologic injury is the most significant long-term morbidity in PPHN survivors.

1. Hypoxic-Ischemic Encephalopathy (HIE)

Severe hypoxemia and hemodynamic instability cause brain injury.

Presentation:

• Altered level of consciousness
• Seizures
• Abnormal tone and reflexes
• Feeding difficulties

Severity:

• Mild (Sarnat Stage 1): Full recovery expected
• Moderate (Sarnat Stage 2): Variable outcomes; 30-50% develop cerebral palsy
• Severe (Sarnat Stage 3): High mortality; survivors have severe disability

Management:

• Therapeutic hypothermia if criteria met (moderate-severe HIE within 6 hours of birth)
• Cooling may worsen PPHN; balance neuroprotection with pulmonary hypertension management

2. Intracranial Hemorrhage

Types:

• Intraventricular Hemorrhage (IVH): More common in preterm, but can occur in term infants with severe PPHN
• Subarachnoid Hemorrhage
• Subdural Hemorrhage: Birth trauma, coagulopathy

Risk Factors:

• Extreme hypoxemia and hypercarbia
• Rapid swings in blood pressure or PaCO2
• ECMO (anticoagulation increases bleeding risk)

3. Sensorineural Hearing Loss (SNHL)

Occurs in 10-20% of PPHN survivors, particularly those requiring ECMO.

Mechanisms:

• Hypoxic injury to cochlea or auditory nerve
• Ototoxic medications (aminoglycoside antibiotics, loop diuretics)
• Acidosis and metabolic derangements
• Hyperbilirubinemia (kernicterus spectrum)

Screening:

• Universal newborn hearing screening (automated auditory brainstem response)
• Repeat screening at 6-12 months in high-risk infants
• Audiology follow-up for all PPHN survivors

4. Cerebral Palsy

Occurs in 7-20% of survivors, depending on severity and associated HIE.

Types:

• Spastic (most common)
• Dyskinetic
• Ataxic
• Mixed

Risk Factors:

• Severe, prolonged hypoxemia
• HIE
• Intracranial hemorrhage
• Sepsis/meningitis

5. Neurodevelopmental Impairment

Beyond cerebral palsy, survivors may have:

• Cognitive delay
• Language delays
• Behavioral difficulties
• Learning disabilities
• Attention deficit disorders

Monitoring:

• Neurodevelopmental follow-up at 6, 12, 18, 24 months and beyond
• Standardized assessments (Bayley Scales of Infant Development)
• Early intervention services for identified delays

C. Cardiovascular Complications

1. Systemic Hypotension and Shock

Common in severe PPHN; managed as discussed above with volume and vasopressor support.

2. Right Ventricular Failure

Severe, prolonged pressure overload causes RV decompensation.

Presentation:

• Worsening systemic perfusion
• Hepatomegaly
• Elevated CVP

Management:

• Aggressive pulmonary vasodilation
• Inotropic support (milrinone, dobutamine)
• ECMO if refractory

3. Left Ventricular Dysfunction

May develop secondary to:

• Septal shift impairing LV filling
• Hypoxemia causing myocardial ischemia
• Excessive afterload reduction (with aggressive vasodilators)

4. Pulmonary Hemorrhage

Rare but life-threatening complication.

Presentation:

• Acute desaturation
• Bloody secretions from endotracheal tube
• Hemodynamic collapse

Management:

• Increase PEEP (tamponade bleeding)
• Decrease pulmonary blood flow (reduce PDA shunt if present)
• Transfuse blood products
• ECMO if refractory

D. Renal and Metabolic Complications

1. Acute Kidney Injury (AKI)

Hypoxemia, hypotension, and nephrotoxic medications cause renal impairment.

Monitoring:

• Serum creatinine, urine output
• Electrolyte abnormalities (hyperkalemia, acidosis)

Management:

• Optimize hemodynamics
• Fluid restriction if oliguric
• Avoid nephrotoxins when possible
• Renal replacement therapy (continuous venovenous hemofiltration) in severe cases, particularly on ECMO

2. Electrolyte Disturbances

Frequent due to medications, renal impairment, and diuretics.

E. Gastrointestinal Complications

1. Necrotizing Enterocolitis (NEC)

Risk factors: hypoxia, hypoperfusion, enteral feeding in hemodynamically unstable infant.

Prevention:

• Delay enteral feeding until stable
• Slow advancement of feeds
• Use of human milk

2. Feeding Difficulties

Prolonged intubation and critical illness cause oral aversion and dysphagia. Speech therapy and occupational therapy often needed.

F. Hematologic Complications

1. Thrombocytopenia

Common in sepsis, DIC, or ECMO.

Management:

• Platelet transfusion if less than 50,000/μL (or less than 100,000/μL if bleeding or pre-procedure)

2. Coagulopathy

DIC in sepsis or on ECMO (anticoagulation).

Management:

• Replace clotting factors (FFP, cryoprecipitate)
• Monitor PT, PTT, fibrinogen

---

10. Prognosis and Long-Term Outcomes

A. Survival

Overall Survival: 75-90% in contemporary series with access to iNO and ECMO. [18]

Survival by Etiology:

• Meconium Aspiration Syndrome: 90-95%
• Idiopathic PPHN: 85-90%
• Sepsis/Pneumonia: 75-85%
• Respiratory Distress Syndrome: 85-90%
• Congenital Diaphragmatic Hernia: 50-70% (most challenging etiology)

Factors Associated with Mortality:

• Severe pulmonary hypoplasia
• Congenital diaphragmatic hernia
• Severe HIE
• Refractory hypotension
• Multi-organ dysfunction
• ECMO complications (intracranial hemorrhage)

B. Neurodevelopmental Outcomes

Normal Development: 50-75% of survivors have normal neurodevelopmental outcomes at 2 years.

Moderate-Severe Impairment: 10-25% demonstrate significant deficits including:

• Cerebral palsy (7-20%)
• Cognitive delay (developmental quotient less than 70)
• Sensorineural hearing loss (10-20%)
• Visual impairment (cortical visual impairment, retinopathy)

Mild Impairment: Additional 10-20% have mild delays or learning difficulties that may not manifest until school age.

Predictors of Adverse Neurodevelopmental Outcome:

• Severe hypoxemia (prolonged PaO2 less than 40 mmHg)
• Hypoxic-ischemic encephalopathy (moderate-severe)
• Intracranial hemorrhage
• Prolonged ECMO course (> 10-14 days)
• Congenital diaphragmatic hernia
• Severe acidosis and metabolic derangements

School-Age Outcomes:

• Increased rates of ADHD, learning disabilities, behavioral problems
• Executive function deficits
• Motor coordination difficulties

C. Respiratory Outcomes

Bronchopulmonary Dysplasia/Chronic Lung Disease:

• 10-25% require supplemental oxygen beyond 28 days of life or 36 weeks postmenstrual age
• Higher in CDH, severe MAS, prolonged ventilation

Reactive Airway Disease:

• Increased incidence of asthma and wheezing in childhood
• May require bronchodilators

Recurrent Respiratory Infections:

• Higher rate of pneumonia, bronchiolitis in first 2 years

Pulmonary Function:

• Long-term pulmonary function generally normal in most survivors without BPD
• Mild restrictive or obstructive patterns in some BPD survivors

D. Cardiovascular Outcomes

Resolution of Pulmonary Hypertension:

• Most infants experience resolution of pulmonary hypertension within days to weeks
• Persistent pulmonary hypertension beyond 3-6 months uncommon (5-10%), may require chronic sildenafil

Chronic Pulmonary Hypertension Risk Factors:

• Underlying pulmonary hypoplasia
• Bronchopulmonary dysplasia
• Genetic pulmonary hypertension predisposition

Cardiac Function:

• RV function typically normalizes as pulmonary pressure resolves
• Rare long-term RV dysfunction

E. Growth and Feeding

Growth:

• Most PPHN survivors have normal growth trajectories
• Growth delay more common in CDH, BPD, or neurologically impaired infants

Feeding Difficulties:

• Oral aversion common after prolonged intubation
• 20-40% require feeding therapy
• Gastrostomy tube placement necessary in 5-15% (higher in CDH, severe neurologic impairment)

F. Follow-Up Recommendations

All PPHN survivors, particularly those requiring iNO or ECMO, should have structured follow-up:

Neonatal Period:

• Serial echocardiography to assess pulmonary pressure resolution
• Cranial imaging (ultrasound or MRI) to identify brain injury

Infancy (0-2 years):

• Neurodevelopmental assessments at 6, 12, 18, 24 months
• Hearing screening (ABR) at discharge and 6-12 months
• Ophthalmologic examination
• Physical therapy, occupational therapy, speech therapy as needed

Childhood:

• School-age neurodevelopmental testing
• Monitor for learning difficulties, behavioral problems
• Pulmonary function testing if chronic respiratory symptoms
• Cardiology follow-up if persistent pulmonary hypertension

---

11. Differential Diagnosis

Severe hypoxemia in a term or near-term newborn has a broad differential. Rapid differentiation between PPHN and cyanotic congenital heart disease is critical, as management differs fundamentally.

A. Cyanotic Congenital Heart Disease

Key Conditions:

1. Transposition of Great Arteries (TGA)

• Most common cyanotic heart disease presenting in newborn period
• Parallel circulations; survival depends on mixing at atrial or ductal level
• Severe cyanosis within hours of birth
• Chest X-ray: "Egg on string" cardiac silhouette
• Echocardiography: Diagnostic (aorta from RV, pulmonary artery from LV)
• Management: Prostaglandin E1 infusion to maintain ductal patency; urgent balloon atrial septostomy; arterial switch operation

2. Total Anomalous Pulmonary Venous Return (TAPVR), Obstructed

• Pulmonary veins drain to systemic venous system rather than left atrium
• Severe hypoxemia if obstructed (restricted pulmonary venous return causes pulmonary edema and secondary pulmonary hypertension)
• Chest X-ray: Severe pulmonary edema ("white out" lungs)
• Echocardiography: Diagnostic
• Management: Emergency surgical repair

3. Hypoplastic Left Heart Syndrome (HLHS)

• Underdeveloped LV, mitral valve, aortic valve, ascending aorta
• Ductal-dependent systemic circulation
• Cyanosis and shock as ductus closes
• Echocardiography: Diagnostic
• Management: Prostaglandin E1; staged surgical palliation (Norwood procedure)

4. Critical Pulmonary Stenosis or Pulmonary Atresia with Intact Ventricular Septum

• Ductal-dependent pulmonary blood flow
• Cyanosis as ductus closes
• Echocardiography: Diagnostic
• Management: Prostaglandin E1; balloon valvuloplasty or surgical intervention

5. Tetralogy of Fallot

• Usually presents later (weeks-months), but severe forms ("tet spells") may present neonatally
• VSD, pulmonary stenosis, overriding aorta, RV hypertrophy
• Chest X-ray: "Boot-shaped" heart
• Echocardiography: Diagnostic
• Management: Prostaglandin E1 if ductal-dependent; surgical repair

Differentiation from PPHN:

• Echocardiography is definitive: Structural abnormalities on echo establish CHD
• Hyperoxia test: PaO2 typically remains less than 100 mmHg in CHD (though also in severe PPHN)
• Response to iNO: No response or worsening in ductal-dependent lesions (closing ductus arteriosus)
• Pre-Post Ductal Gradient: May be absent or reversed in some CHD lesions

B. Pulmonary Parenchymal Disease

1. Meconium Aspiration Syndrome (MAS)

• Most common cause of PPHN
• History of meconium-stained amniotic fluid
• Chest X-ray: Patchy infiltrates, hyperinflation
• Management overlaps with PPHN (gentle ventilation, iNO, surfactant)

2. Respiratory Distress Syndrome (RDS)

• Late preterm infants (34-37 weeks)
• Surfactant deficiency
• Chest X-ray: Ground-glass opacification, air bronchograms
• Management: Surfactant, CPAP/ventilation; may develop secondary PPHN

3. Congenital Pneumonia/Sepsis

• Maternal risk factors (prolonged rupture of membranes, chorioamnionitis, GBS colonization)
• Systemic signs of sepsis (temperature instability, hypotension, neutropenia/neutrophilia)
• Chest X-ray: Variable infiltrates
• Management: Antibiotics, supportive care

4. Transient Tachypnea of the Newborn (TTN)

• Delayed fetal lung fluid clearance (more common after C-section without labor)
• Mild-moderate respiratory distress
• Chest X-ray: Perihilar streaking, fluid in fissures
• Usually self-limited; occasionally causes mild secondary PPHN

C. Structural Lung/Thoracic Abnormalities

1. Congenital Diaphragmatic Hernia (CDH)

• Herniation of abdominal contents into thorax
• Pulmonary hypoplasia and severe PPHN
• Chest X-ray: Bowel gas in chest, mediastinal shift, scaphoid abdomen
• Management: Gentle ventilation, iNO, ECMO if refractory; delayed surgical repair after stabilization

2. Congenital Pulmonary Airway Malformation (CPAM)

• Cystic or solid lung masses
• Respiratory distress if large
• Chest X-ray or CT: Cystic lesions
• Management: Supportive; surgical resection

3. Pleural Effusions (Hydrops Fetalis)

• Antenatal diagnosis typically
• Severe respiratory distress
• Chest X-ray: Large effusions
• Management: Thoracentesis, treat underlying cause

D. Neuromuscular and Central Causes

1. Central Hypoventilation

• Maternal sedating medications
• Encephalopathy (HIE)
• Management: Ventilatory support

2. Neuromuscular Disease

• Congenital myopathies, myasthenia gravis
• Weakness, hypotonia
• Management: Ventilatory support, treat underlying condition

E. Hematologic Causes

1. Severe Anemia

• Feto-maternal hemorrhage, twin-twin transfusion, hemolysis
• Pallor, tachycardia, shock
• Management: Blood transfusion

2. Polycythemia (Hematocrit > 65-70%)

• Delayed cord clamping, maternal diabetes, IUGR, twin-twin transfusion recipient
• Increased blood viscosity worsens pulmonary hypertension
• Management: Partial exchange transfusion

3. Methemoglobinemia

• Oxidizing agents, inherited enzyme deficiencies
• "Chocolate" colored blood
• Measure methemoglobin level
• Management: Methylene blue if symptomatic

---

12. Patient and Layperson Explanation

What is PPHN?

Persistent Pulmonary Hypertension of the Newborn, or PPHN, is a serious breathing problem that affects some newborn babies. To understand it, we need to think about how a baby's circulation changes at birth.

Before birth, while a baby is still in the womb, their lungs are filled with fluid and are not used for breathing. Instead, the mother's placenta provides oxygen to the baby through the umbilical cord. Because the baby's lungs aren't working yet, the body has special "shortcuts" that allow blood to bypass the lungs. These shortcuts are called the ductus arteriosus (a blood vessel connecting the lung artery to the main body artery) and the foramen ovale (a hole between the two upper chambers of the heart).

At birth, when the baby takes their first breath, the lungs fill with air and expand. This causes the blood vessels in the lungs to relax and open up, allowing blood to flow through the lungs to pick up oxygen. The shortcuts that were used before birth close up because they're no longer needed.

In PPHN, something goes wrong with this transition. The blood vessels in the lungs stay tight and squeezed shut, maintaining high pressure in the lungs (that's the "pulmonary hypertension" part). Because of this high pressure, blood can't flow through the lungs properly. Instead, blood takes the "old shortcuts" (the ductus and foramen ovale) and bypasses the lungs entirely. This means the blood circulating through the baby's body hasn't picked up enough oxygen, causing the baby to turn blue (cyanotic) and become very sick.

Why does PPHN happen?

There are several reasons why a baby might develop PPHN:

1. Stress during delivery: If the baby experienced a difficult birth, such as being deprived of oxygen, swallowing meconium (the baby's first stool, which is dark and sticky), or developing an infection, their body may react by keeping the lung blood vessels tight.

2. Underdeveloped lungs: Some babies are born with lungs that didn't grow properly in the womb. This can happen if there was a problem like a diaphragmatic hernia (where organs from the belly push into the chest) or if there wasn't enough amniotic fluid around the baby.

3. Unknown reasons: Sometimes PPHN happens even when everything seemed normal during pregnancy and delivery. This is called "idiopathic" PPHN. It may be related to medications the mother took during pregnancy or other factors we don't fully understand yet.

What are the signs?

Babies with PPHN usually show symptoms shortly after birth:

• Blue color (cyanosis), especially around the lips and face
• Difficulty breathing, with fast breathing, grunting sounds, and visible chest retractions (the skin pulling in between the ribs)
• Low oxygen levels, even when given extra oxygen
• Instability, where small things like being touched or moved can cause sudden drops in oxygen levels

One unique sign is called differential cyanosis, where the baby's right hand looks pinker (has more oxygen) than their feet. This happens because the blood going to the right hand comes from before the "shortcut," while blood to the feet has gone through the shortcut and missed the lungs.

How is PPHN diagnosed?

Doctors will do several tests:

• Pulse oximetry: Sensors on the baby's hand and foot measure oxygen levels and can show the difference described above.
• Echocardiogram (heart ultrasound): This is the most important test. It shows the structure of the heart, measures the pressure in the lungs, and can see if blood is flowing through those old shortcuts. It also helps make sure the baby doesn't have a structural heart problem that looks similar to PPHN but needs different treatment.
• Blood tests: Check oxygen and carbon dioxide levels in the blood, and look for signs of infection.
• Chest X-ray: Shows what the lungs look like and can help identify why PPHN developed.

How is PPHN treated?

Treatment focuses on helping the blood vessels in the lungs relax and open up, while supporting the baby's breathing and blood pressure:

1. Oxygen: Giving the baby extra oxygen helps the lung blood vessels relax.

2. Breathing support: Most babies need help breathing with a ventilator (breathing machine). The goal is to gently support the lungs without causing damage.

3. Nitric oxide gas (the "magic gas"): This is often the key treatment. The baby breathes in a special gas called nitric oxide mixed with oxygen. When nitric oxide reaches the lungs, it makes the blood vessels there relax and open up. Importantly, it only works in the lungs and doesn't affect the rest of the body. This helps blood flow through the lungs to pick up oxygen. Many babies improve dramatically within 30 minutes to an hour of starting this treatment.

4. Medications:

• Sedation: Keeping the baby calm and still is very important because even small disturbances can cause the lung blood vessels to tighten again.
• Blood pressure medications: Sometimes the baby needs medicines to keep their blood pressure up so that blood flows in the right direction.
• Sildenafil (similar to Viagra): This medication can help keep the lung blood vessels relaxed. It's sometimes given as a pill or through an IV.

5. ECMO (heart-lung bypass machine): For the sickest babies who don't improve with other treatments, a machine can take over the work of the heart and lungs temporarily. Blood is taken out of the baby's body, the machine adds oxygen to it, and then it's returned to the body. This gives the lungs time to rest and heal. ECMO is a very serious treatment used only in specialized hospitals, but it can be lifesaving. About 75-85% of babies who need ECMO for PPHN survive.

What is the recovery like?

In the hospital: Most babies need to stay in the neonatal intensive care unit (NICU) for at least several days to several weeks. As their lungs improve, the doctors will slowly reduce the breathing support and medications.

Going home: Many babies recover completely and can go home breathing on their own, eating well, and developing normally. Some babies may need to continue oxygen at home for a while.

Follow-up care: Because PPHN is a serious condition, babies need close follow-up after leaving the hospital. This includes:

• Hearing tests: The illness and some of the treatments can affect hearing, so this needs to be checked.
• Developmental assessments: Doctors will monitor the baby's growth, learning, and development over time to make sure they're on track.
• Heart checks: Occasionally, babies may need follow-up heart ultrasounds to make sure the lung pressures have returned to normal.

What is the long-term outlook?

The good news: Most babies (about 75-90%) survive PPHN and go on to live healthy, normal lives.

Possible challenges:

• About 10-25% of babies may have some developmental delays or learning challenges as they grow. This is more common in babies who were very sick or needed ECMO.
• Some babies may have chronic lung problems and need medications for asthma-like symptoms.
• Hearing loss occurs in about 10-20% of survivors, which is why regular hearing checks are important.

What can parents do?

PPHN is a frightening and stressful experience for families. Here are some important things to know:

• It's not your fault: PPHN is not caused by anything the parents did or didn't do.
• Ask questions: The NICU team is there to help. Don't hesitate to ask for explanations, updates, or clarification about anything you don't understand.
• Stay involved: Even though your baby is very sick, you can still be close to them. Talk to them, touch them gently when the nurses say it's okay, and participate in their care as much as possible.
• Take care of yourself: This is a marathon, not a sprint. Make sure you're eating, sleeping (as much as possible), and getting emotional support.
• Connect with others: Many hospitals have support groups or can connect you with other families who have been through similar experiences.

PPHN is a serious condition, but with modern treatments like inhaled nitric oxide and ECMO, the vast majority of babies recover and thrive.

---

13. References

1. Singh Y, Lakshminrusimha S. Pathophysiology and Management of Persistent Pulmonary Hypertension of the Newborn. Clin Perinatol. 2021;48(3):595-618. doi:10.1016/j.clp.2021.05.009. PMID: 34353582.

2. Mandell E, Kinsella JP, Abman SH. Persistent pulmonary hypertension of the newborn. Pediatr Pulmonol. 2021;56(3):661-669. doi:10.1002/ppul.25073. PMID: 32930508.

3. Sankaran D, Lakshminrusimha S. Pulmonary hypertension in the newborn- etiology and pathogenesis. Semin Fetal Neonatal Med. 2022;27(4):101381. doi:10.1016/j.siny.2022.101381. PMID: 35963740.

4. Lakshminrusimha S, Keszler M. Persistent Pulmonary Hypertension of the Newborn. Neoreviews. 2015;16(12):e680-e692. doi:10.1542/neo.16-12-e680. PMID: 26783388.

5. Fuloria M, Aschner JL. Persistent pulmonary hypertension of the newborn. Semin Fetal Neonatal Med. 2017;22(4):220-226. doi:10.1016/j.siny.2017.03.004. PMID: 28342684.

6. Alhumaid S, Al Ghamdi MA, Al Omair AA, et al. International treatment outcomes of neonates on extracorporeal membrane oxygenation (ECMO) with persistent pulmonary hypertension of the newborn (PPHN): a systematic review. J Cardiothorac Surg. 2024;19(1):488. doi:10.1186/s13019-024-03011-3. PMID: 39182148.

7. Chandrasekharan PK, Rawat M, Madappa R, Rothstein DH, Lakshminrusimha S. Congenital Diaphragmatic hernia - a review. Matern Health Neonatol Perinatol. 2017;3:6. doi:10.1186/s40748-017-0045-1. PMID: 28331629.

8. Osman A, El-Farrash RA, Elmasry SA, El-Nemer AE. Meconium aspiration syndrome: a comprehensive review. J Perinatol. 2023;43(10):1211-1219. doi:10.1038/s41372-023-01708-2. PMID: 37543651.

9. Sankaran D, Chandrasekharan P, Gugino SF, et al. Meconium Aspiration Syndrome, Hypoxic-Ischemic Encephalopathy and Therapeutic Hypothermia-A Recipe for Severe Pulmonary Hypertension? Children (Basel). 2024;11(6):673. doi:10.3390/children11060673. PMID: 38929252.

10. Cookson MW, Lakshminrusimha S. Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension. Clin Perinatol. 2024;51(1):171-188. doi:10.1016/j.clp.2023.11.001. PMID: 38325949.

11. Mitra S, Florez ID, Murthy K, et al. Inhaled nitric oxide use in newborns: a Paediatr Child Health. 2023;28(2):135-145. doi:10.1093/pch/pxac107. PMID: 37151928.

12. Fei Q, Lin J, Zhou D, et al. Comparison of Different Treatments of Persistent Pulmonary Hypertension of the Newborn: A Systematic Review and Network Meta-Analysis. Crit Care Med. 2024;52(7):1109-1119. doi:10.1097/CCM.0000000000006227. PMID: 38363176.

13. Kallimath A, Akhtar J, Raghuram HM, et al. Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial. BMC Pediatr. 2024;24(1):659. doi:10.1186/s12887-024-05107-0. PMID: 39487423.

14. Kinsella JP, Truog WE, Walsh WF, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr. 1997;131(1 Pt 1):55-62. doi:10.1016/s0022-3476(97)70124-0. PMID: 9252111.

15. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med. 2000;342(7):469-474. doi:10.1056/NEJM200002173420704. PMID: 10675427.

16. Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022;327(14):1379-1391. doi:10.1001/jama.2022.4402. PMID: 35412560.

17. Schmidt AR, Ramamoorthy C. Bronchopulmonary dysplasia. Paediatr Anaesth. 2022;32(2):174-180. doi:10.1111/pan.14365. PMID: 34877749.

18. Austin ED, Hamrick SEG, Ivy DD, et al. Pulmonary Hemodynamics and Long-Term Outcomes in Children with Pulmonary Hypertension-Associated Bronchopulmonary Dysplasia. J Pediatr. 2025;277:114869. doi:10.1016/j.jpeds.2025.114869. PMID: 41139016.

19. Chaudhari T, Goss KN, Sachdeva R, et al. Diagnosis, management and long term cardiovascular outcomes of phenotypic profiles in pulmonary hypertension associated with bronchopulmonary dysplasia. Prog Pediatr Cardiol. 2024;73:101707. doi:10.1016/j.ppedcard.2024.101707. PMID: 38590769.

20. Jirapaet KS, Kinsella JP, Abman SH. Comparison of high-frequency flow interruption ventilation and hyperventilation in persistent pulmonary hypertension of the newborn. Pediatr Pulmonol. 2001;31(6):428-435. doi:10.1002/ppul.1071. PMID: 11353547.

---

Document Statistics:

• Total Lines: 985
• Word Count: ~11,500
• Citations: 20 (PubMed-indexed)
• Last Updated: 2026-01-06